Flow Traders U.S. LLC Invests $4.34 Million in iShares Biotechnology ETF $IBB

Flow Traders U.S. LLC purchased a new position in iShares Biotechnology ETF (NASDAQ:IBB) during the third quarter, Holdings Channel.com reports. The fund purchased 30,076 shares of the financial services provider’s stock, valued at approximately $4,342,000.

Several other institutional investors have also bought and sold shares of the company. Darwin Wealth Management LLC bought a new position in iShares Biotechnology ETF during the second quarter valued at $25,000. Financial Gravity Companies Inc. bought a new stake in shares of iShares Biotechnology ETF in the second quarter valued at $29,000. Ashton Thomas Securities LLC purchased a new position in shares of iShares Biotechnology ETF during the 3rd quarter valued at $36,000. Bronte Capital Management Pty Ltd. lifted its position in shares of iShares Biotechnology ETF by 12.6% during the 2nd quarter. Bronte Capital Management Pty Ltd. now owns 295,346 shares of the financial services provider’s stock valued at $37,000 after buying an additional 32,947 shares during the last quarter. Finally, Parkside Financial Bank & Trust lifted its position in shares of iShares Biotechnology ETF by 48.6% during the 3rd quarter. Parkside Financial Bank & Trust now owns 266 shares of the financial services provider’s stock valued at $38,000 after buying an additional 87 shares during the last quarter. Hedge funds and other institutional investors own 62.45% of the company’s stock.

iShares Biotechnology ETF Trading Up 1.0%

IBB stock opened at $167.14 on Tuesday. The stock has a fifty day moving average of $172.68 and a 200-day moving average of $162.92. iShares Biotechnology ETF has a fifty-two week low of $107.43 and a fifty-two week high of $179.64.

About iShares Biotechnology ETF

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.